Documents

Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.

2026

Investor presentation

Jun 23, 2026

Profitable, asset-light cannabis platform drives growth with innovation and telemedicine.

Earnings, Q1 FY2026

May 11, 2026

Q1 2026 saw higher profitability, strong UK growth, and a robust financial position.

2025

Earnings, H2 FY2025

May 8, 2026

Revenue up 78% to €3.9M, net income €126K, audit unqualified, all sales intra-group.

Earnings, Q3 FY2025

Oct 30, 2025

Revenue up 148% year-over-year to EUR 75 million, with strong growth and European expansion plans.

Earnings, H1 FY2025

Oct 16, 2025

Revenue and profit fell, but equity and liquidity remain robust amid higher compliance costs.

Earnings, Q2 FY2025

Jul 11, 2025

Q2 2025 revenue more than doubled year-over-year, exceeding last year's total annual sales.

Earnings, Q1 FY2025

Apr 10, 2025

Q1 2025 revenue soared to EUR 25.6 million, quadrupling year-over-year on robust European demand.

2024

Earnings, H2 FY2024

May 2, 2025

Revenue and net income grew strongly, with all earnings retained and a clean audit opinion.

Earnings, H1 FY2024

Oct 30, 2024

Net profit surged to €210,989.14 in H1 2024, driven by higher revenue and one-time income.

2023

Earnings, H2 FY2023

May 14, 2024

Earnings, H1 FY2023

Oct 30, 2023

Cantourage Group SE

Documents